Share on StockTwits

Research analysts at Laidlaw started coverage on shares of ISIS Pharmaceuticals (NASDAQ:ISIS) in a report released on Tuesday. The firm set a “buy” rating on the stock.

In other ISIS Pharmaceuticals news, CEO Stanley T. Crooke unloaded 16,000 shares of the company’s stock on the open market in a transaction that occurred on Friday, August 1st. The stock was sold at an average price of $30.53, for a total transaction of $488,480.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.

A number of other analysts have also recently weighed in on ISIS. Analysts at Laidlow & Co. initiated coverage on shares of ISIS Pharmaceuticals in a research note on Tuesday. They set a “buy” rating and a $52.00 price target on the stock. Separately, analysts at Zacks reiterated a “neutral” rating on shares of ISIS Pharmaceuticals in a research note on Thursday, August 7th. They now have a $35.00 price target on the stock. Finally, analysts at Summer Street reiterated a “neutral” rating on shares of ISIS Pharmaceuticals in a research note on Friday, May 23rd. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and seven have issued a buy rating to the company’s stock. ISIS Pharmaceuticals currently has a consensus rating of “Hold” and an average price target of $42.64.

ISIS Pharmaceuticals (NASDAQ:ISIS) traded down 1.24% during mid-day trading on Tuesday, hitting $34.36. The stock had a trading volume of 356,204 shares. ISIS Pharmaceuticals has a 1-year low of $22.25 and a 1-year high of $62.66. The stock has a 50-day moving average of $32.17 and a 200-day moving average of $37.56. The company’s market cap is $4.045 billion.

ISIS Pharmaceuticals (NASDAQ:ISIS) last posted its quarterly earnings results on Monday, August 4th. The company reported ($0.10) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.12) by $0.02. The company had revenue of $57.08 million for the quarter, compared to the consensus estimate of $45.60 million. During the same quarter in the previous year, the company posted ($0.09) earnings per share. The company’s revenue for the quarter was up 49.8% on a year-over-year basis. Analysts expect that ISIS Pharmaceuticals will post $-0.73 EPS for the current fiscal year.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.